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Abstract Therapies directed against VEGF-A and its
receptors are effective in treating many mouse tumors but
have been less so in treating human cancer patients. To
elucidate the reasons that might be responsible for this
difference in response, we investigated the nature of the
blood vessels that appear in human and mouse cancers and
the tumor ‘‘surrogate’’ blood vessels that develop in
immunodeﬁcient mice in response to an adenovirus
expressing VEGF-A
164. Both tumor and tumor surrogate
blood vessels are heterogeneous and form by two distinct
processes, angiogenesis and arterio-venogenesis. The ﬁrst
new angiogenic blood vessels to form are mother vessels
(MV); MV arise from preexisting venules and capillaries
and evolve over time into glomeruloid microvascular pro-
liferations (GMP) and subsequently into capillaries and
vascular malformations (VM). Arterio-venogenesis results
from the remodeling and enlargement of preexisting
arteries and veins, leading to the formation of feeder
arteries (FA) and draining veins (DV) that supply and drain
angiogenic vessels. Of these different blood vessel types,
only the two that form ﬁrst, MV and GMP, were highly
responsive to anti-VEGF therapy, whereas ‘‘late’’-formed
capillaries, VM, FA and DV were relatively unresponsive.
This ﬁnding may explain, at least in part, the relatively
poor response of human cancers to anti-VEGF/VEGFR
therapies, because human cancers, present for months or
years prior to discovery, are expected to contain a large
proportion of late-formed blood vessels. The future of anti-
vascular cancer therapy may depend on ﬁnding new targets
on ‘‘late’’ vessels, apart from those associated with the
VEGF/VEGFR axis.
Keywords Angiogenesis  VPF/VEGF-A 
Ad-VEGF-A
164  Aﬂibercept (VEGF Trap)  Rapamycin
It has been known for some time that most tumors need to
generate a vascular supply if they are to grow beyond small
size. Folkman [1] proposed that tumors induced the for-
mation of new blood vessels by secreting a ‘‘tumor angi-
ogenesis factor’’ or ‘‘TAF’’. It is now clear that a number of
growth factors can induce angiogenesis, and tumors can
secrete many of them. However, it is also generally agreed
that the most important TAF, at least for initial tumor
growth, is vascular permeability factor/vascular endothelial
growth factor (VPF/VEGF or, more simply, VEGF-A)
[2, 3]. Further, although VEGF-A interacts with a number
of different receptors, VEGFR-2 (KDR, ﬂk-1) is the one
that is essential for the signaling pathways that promote
angiogenesis and vascular permeability [4].
Folkman also proposed that drugs targeting TAFs would
be effective in preventing tumor growth [1], and therefore
there was great excitement when it was shown that anti-
bodies to VEGF-A inhibited ﬂuid accumulation in the case
of ascites tumors [5] and prevented the growth of many
solid mouse tumors and tumor xenografts [6, 7]. Based on
these animal studies, it was anticipated that therapies
directed against VEGF-A or VEGFR-2 would open a new
phase of therapy against human cancers. Unfortunately, the
promise of this approach has not yet been fulﬁlled. Bev-
acizumab (Avastin; Genentech), a humanized monoclonal
antibody directed against VEGF-A and the most studied of
the anti-VEGF-A/VEGFR drugs, prolongs the life of
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and then only when accompanied by chemotherapy [8].
When administered along with chemotherapy, bev-
acizumab and small molecule receptor tyrosine kinase
inhibitors directed against VEGFR-2 are of some beneﬁt in
several other cancers; however, although these therapies
often prolong progression-free survival by a matter of
months, they generally do not extend life [9]. Therefore,
they are not the blockbusters that had been hoped for and
some have wondered whether they are ‘‘boon or bust’’ [10].
Why have these drugs not been more successful in treating
human cancer, given their widely agreed upon effective-
ness in mice? A number of reasons have been offered and
will be considered here. However, before addressing this
important question, we will ﬁrst consider two other issues
that provide insight into the failure of anti-VEGF/VEGFR
therapy to work better. These are a description of the types
of blood vessels that VEGF-A-secreting tumors generate
and the steps and mechanisms by which these blood vessels
form.
Heterogeneity of the tumor vasculature
Warren [11] in the late 1970s, and we and others more
recently (reviewed in [12–14]), have analyzed the types of
blood vessels that are found in tumors. These studies have
shown that the tumor vasculature is highly heterogeneous,
and, for the most part, very different from that found in
normal tissues. Examining several human cancers, we were
able to identify six distinct tumor blood vessel types
(Table 1). Further, using an adenovirus engineered to
express VEGF-A
164, we were able to replicate each of
these in the form of tumor ‘‘surrogate’’ vessels in immu-
nodeﬁcient mice [14, 15]. This model system allowed us to
elucidate the steps and mechanisms by which each vessel
type formed initially and evolved over time (Fig. 1).
Unlike tumors, which express high levels of VEGF-A over
extended periods of time, Ad-VEGF-A
164 gives rise to a
single pulse of VEGF-A
164. This VEGF-A
164 pulse is ini-
tially of similar magnitude to that found in many tumors.
However, unlike in tumors, local VEGF-A
164 levels fall off
dramatically over a matter of weeks because the adenoviral
insert carrying the transgene is not integrated into the
cellular genome and so is discarded from the cell. In
contrast, tumors continue to express VEGF-A at high levels
over long periods of time; thus, they continually induce the
formation of new blood vessels, while, concurrently,
causing previously formed vessels to differentiate into
more stable forms. Given this mixture of ‘‘early’’ and
‘‘late’’ vessels, it becomes difﬁcult to follow progression of
newly formed vessels as they evolve over time in tumors.
In contrast, at Ad-VEGF-A
164 injection sites, the formation
of new blood vessels is restricted temporally and their
evolution into late vessels can therefore be followed
sequentially. Studies with the Ad-VEGF-A
164 model
demonstrated that four of the six tumor vessel ‘‘surrogates’’
develop by angiogenesis, i.e., they derive initially from
preexisting small blood vessels, namely, venules and cap-
illaries. In addition, both VEGF-A-secreting tumors and
Ad-VEGF-A
164 induce abnormal arteriogenesis and veno-
genesis, i.e., they cause pre-existing arteries and veins to
enlarge and remodel and these feed and drain the angio-
genic vascular bed. There is every reason to believe that
similar processes are going on in tumors.
Types of tumor and tumor ‘‘surrogate’’ blood vessels
and their generation
‘‘Mother’’ vessels (MV) are the ﬁrst new type of angio-
genic blood vessel to appear, both in tumors and also in
response to Ad-VEGF-A
164 [15, 16] (Fig. 1). MV are
greatly enlarged sinusoids that are highly permeable to
Table 1 Classiﬁcation of tumor/tumor surrogate blood vessels
Process involved Vessel type Vessel properties
Angiogenesis Mother vessels (MV) Large, thin-walled, hyperpermeable, lightly fenestrated pericyte-poor
sinusoids that are engorged with red blood cells.
Capillaries Formed from MV by a process that involves intra-luminal bridging and
intussusception.
Glomeruloid microvascular
proliferations (GMP)
Poorly organized vascular structures that resemble renal glomeruli
macroscopically. GMP are comprised of endothelial cells and pericytes
with minimal vascular lumens and reduplicated basement membranes.
Vascular malformations (VM) Mother vessels that have acquired an often asymmetric coat of smooth
muscle cells and/or ﬁbrous connective tissue.
Arterio-venogenesis Feeder arteries (FA) Enlarged, often tortuous arteries and veins that are derived from preexisting
arteries and veins. They extend radially from the tumor mass, supplying
and draining the angiogenic vessels within.
Draining veins (DV)
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123plasma proteins and to other circulating macromolecules
[13, 14]. They begin to develop from preexisting venules
and capillaries within hours of injection of tumor cells or of
Ad-VEGF-A
164 into mouse tissues. We predicted that
vascular basement membrane (BM) degradation would be
an important step in MV development because BM are
non-compliant (non-elastic) structures that normally
restrict microvessel expansion [17]. Swayne had demon-
strated the importance of BM in maintaining microvessel
size in studies by demonstrating that progressive increases
in intravascular pressure were only able to increase vas-
cular cross-sectional area by *30 % before vessels burst
[18], i.e., far less than the three to ﬁve-fold increase in area
typical of MV. Testing this hypothesis, we found that over
the course of a few days after injecting Ad-VEGF-A
164 or
tumor cells into mouse tissues, BM staining for laminin and
type IV collagen, the most abundant components of vas-
cular BM, was progressively lost in developing MV [17].
Further, western blots revealed progressive fragmentation
of both proteins. Gene chip studies revealed that cathepsin
transcripts were increased locally, and this ﬁnding was
conﬁrmed and extended by RT-PCR and at the protein
level by immunohistochemistry. Further, western blots
revealed that activated forms of three cathepsins, B, S, and
L, increased substantially as MV developed, and immu-
nohistochemistry selectively localized increased cathepsin
activity to the pericytes associated with developing MV. In
normal tissues the action of cathepsins is opposed by a
family of endogenous inhibitors called cysteine protease
inhibitors (CPI). As MV formed, expression of these
inhibitors progressively decreased in both endothelial cells
and pericytes. Thus, BM degradation was induced in MV
by increased expression of cathepsins and decreased
expression of CPI, i.e., by an upsetting of the cathepsin/CPI
balance that normally maintains BM integrity and so
microvascular size. As a consequence of BM degradation,
pericytes lost their attachments to endothelial cells, and
endothelial cells, no longer restrained by BM or attached
pericytes, underwent cellular thinning as their lumens
expanded in response to intravascular pressure. Increased
lumen size requires an increase in endothelial cell surface
area and so an increase in plasma membrane. This was
provided, at least in part, by vesiculo-vacuolar organelles
(VVOs), clusters of hundreds of interconnected vesicles
and vacuoles contained within the cytoplasm of normal
venular endothelial cells [19]. VVOs have an important
role in the transport of macromolecules across venules in
the acute vascular hyperpermeability induced by VEGF-A,
histamine, etc. [20, 21]. The membrane stored in VVOs
amounts to more than twice that found in the plasma
membranes of normal venular endothelial cells. As the
formerly cuboidal endothelial cells of normal venules
Fig. 1 Schematic diagram of the steps by which VEGF-A
164-induces angiogenesis and arterio-venogenesis. The blood vessels responsive to
anti-VEGF-A therapy are enclosed within the box outlined with a dashed line. (Modiﬁed after Fig. 1 in [27])
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123ﬂattened, VVOs fused with the plasma membrane, con-
tributing to the plasma membrane expansion necessary for
MV formation.
MV are typically unstable blood vessels as their lack of
pericytes, basement membrane support, and sluggish blood
ﬂow make them susceptible to thrombosis or collapse. MV
are therefore transitional structures that evolve into one or
another type of daughter vessel: capillaries, glomeruloid
microvascular proliferations (GMP) and vascular malfor-
mations (VM) [13, 14] (Fig. 1).
Capillaries form from MV by a process of internal
bridging as endothelial cells extend thin, ‘‘tip-cell-like’’
processes into the MV lumen rather than externally as in
vascular ‘‘sprouting’’ [13, 14]. These endothelial cell pro-
cesses grow to form transluminal bridges that divide MVs
into smaller, capillary-sized structures that eventually
separate from each other by a process of intussusception.
GMP result from a proliferation of endothelial cells and
pericytes that ﬁll MV lumens and divide them into much
smaller channels that are enveloped by redundant layers of
BM [15, 22]. Like MV, GMP are hyperpermeable to
macromolecules, but, because they are poorly perfused,
account for relatively little plasma extravasation. Finally,
vascular malformations (VM) derive from MV that have
acquired a supporting smooth muscle cell coating. VM are
readily distinguished from normal arteries and veins by
their inappropriately large size (for their location) and by
their thinner and often asymmetric muscular coat. They,
and the capillaries that form in parallel, are not hyperper-
meable to plasma proteins.
In addition to inducing angiogenesis, tumors and
Ad-VEGF-A
164 also stimulate abnormal arteriogenesis and
venogenesis, leading to the formation of the large, often
tortuous feeder arteries (FA) and draining veins (DV) that
supply and drain the tumor microvasculature [13, 14]. The
mechanisms by which these vessels develop have been
little investigated. However, once induced to form in
response to Ad-VEGF-A
164, FA and DV, like VM, per-
sisted indeﬁnitely.
Why doesn’t anti-VEGF-A/VEGFR therapy work
better in cancer patients?
A number of reasons have been offered for the disap-
pointing ineffectiveness of anti-VEGF/VEGFR drugs in
treating human cancers [23–25]. These include the need for
better dosing strategies; the frailty of cancer patients who
are much sicker than tumor-bearing mice and therefore
cannot withstand the toxicities associated with high
dose therapy; and ‘‘vascular normalization’’, a period of
time following anti-VEGF/VEGFR therapy in which
tumor vessels normalize structurally and lose their
hyperpermeability. An additional important reason is that
an impaired vascular supply may not result in the killing of
all tumor cells, leaving survivors hypoxic. Hypoxic tumor
cells reprogram their transcriptional proﬁle to increase the
synthesis of VEGF-A as well as panoply of other growth
factors that together can overwhelm anti-angiogenesis
therapy.
All of the reasons listed above are valid. However, they
seem insufﬁcient to explain fully the lack of anti-VEGF/
VEGFR drug effectiveness in cancer patients relative to
those in mice, and other possibilities must be considered.
Closer inspection of published mouse tumor data provides
some clues. The major successes of anti-VEGF-A/VEGFR
therapies in mice have been in the prevention of the growth
of freshly transplanted mouse tumors and tumor xenografts
[23, 26] (for additional references, see [27, 28]). In con-
trast, when anti-VEGF/VEGFR therapy is delayed and
administered to mice that have established autochthonous
or transplanted tumors, the beneﬁts are of lesser magnitude
[23, 26]. Obviously the difference in treatment regimen
timing is important because freshly transplanted tumors do
not mimic human cancer; in patients, cancers have been
growing for months or years before they are discovered and
treated. The better question, then, becomes, why does anti-
VEGF-A/VEGFR therapy work better on newly trans-
planted tumors than on established tumors?
We suggest that the different types of blood vessels that
tumors induce are likely to provide important insights. As
noted, tumor blood vessels are heterogeneous and form
linearly over time by two distinct but interrelated pro-
cesses, angiogenesis and arterio-venogenesis (Fig. 1). The
initial or ‘‘early’’ vessels induced by VEGF-A are MV and
actively remodeling arteries and veins; these subsequently
evolve over a period of weeks to months into stable ‘‘late’’
vessels, i.e., capillaries, VM, FA and DV. Based on this
understanding of tumor vessel development, we postulated
that ‘‘early’’ and ‘‘late’’ vessels might differ in their sus-
ceptibility to anti-VEGF-A/VEGFR therapy. We offer the
hypothesis that ‘‘early’’ vessels are susceptible to anti-
VEGF-A/VEGFR therapy whereas ‘‘late’’ vessels, though
formed from ‘‘early’’ vessels that are induced by VEGF-A,
have lost their VEGF-A dependence and have therefore
become resistant to anti-VEGF-A/VEGFR therapy. Estab-
lished tumors, whether mouse or human, are expected to
contain a mixture of ‘‘early’’ and ‘‘late’’ vessels. ‘‘Early’’
vessels would predominate initially; however, as tumors
grow over time, the population of ‘‘late’’ vessels would be
expected to become proportionately greater.
The hypothesis just put forward has consequences. It
predicts that 1. ‘‘Late’’ vessels are less dependent on
exogenous VEGF-A than ‘‘early’’ vessels and 2. ‘‘Late’’
vessels are relatively resistant to anti-VEGF-A/VEGFR
therapy compared with ‘‘early’’ vessels.
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of ‘‘early’’ and ‘‘late’’ vessels to agents interfering
with the VEGF-A/VEGFR axis
If our hypothesis has merit, then ‘‘late’’ vessels should be
less dependent on the VEGF/VEGFR axis than ‘‘early’’
vessels. Initial experiments demonstrated that ‘‘early’’
vessels such as MV and GMP stained strongly for VEGFR-2,
the VEGF-A receptor responsible for both VEGF-A-induced
angiogenesis and increased permeability; in contrast, staining
for VEGFR-2 was greatly reduced or largely negative in VM,
FA and DV [28]. This ﬁnding, consistent with our hypothesis,
suggests that VEGFR-2 signaling is less important in ‘‘late’’
than in ‘‘early’’ vessels.
To test our hypothesis more directly, we evaluated the
effects of two drugs that act at different stages in VEGF-A
signaling [28, 29]. One such drug, rapamycin, inhibits
mTOR, a downstream target of the VEGF-A-Akt pathway.
When administered before and coincident with Ad-VEGF-
A
164 injection into tissues, rapamycin effectively inhibited
local vascular Akt and S-6 phosphorylation and prevented
the formation of MV and the vascular hyperpermeability
and edema that accompany their formation [29]. When
administered slightly later, at a time when MV had already
formed, differentiation of MV into GMP and VM was
greatly reduced. However, when administered still later,
when VM, FA and DV predominated, rapamycin had little
effect.
Very recently we obtained similar results with a second
drug, Aﬂibercept (VEGF-Trap). Aﬂibercept is a human
soluble decoy receptor protein with high afﬁnity for all of
the VEGF-A isoforms, as well as for VEGF-B and pla-
cental growth factor [30]. When administered prior to or
shortly after Ad-VEGF-A
164, MV and GMP formation
were prevented and both angiogenesis and arterio-veno-
genesis were strikingly inhibited, as judged both by his-
tology and by quantitative analysis using a double tracer
method that measured total intravascular plasma volume as
well as leaked plasma [28]. However, when given
2 months after Ad-VEGF-A
164 injection, VEGF Trap had
no signiﬁcant effect on the VM, FA and DV that had by
this time become well established.
Together these experiments indicate that ‘‘early’’ and
‘‘late’’ vessels differ substantially, not only in structure but
also in their dependence on ‘‘exogenous’’ VEGF-A, and
therefore their responsiveness to anti-VEGF therapy
(Fig. 1). This does not imply, however, that the endothelial
cells of ‘‘late’’ vessels are entirely VEGF-A-independent.
Pericytes and smooth muscle cells that are in intimate con-
tact with endothelial cells are known to be a source of
VEGF-A and may well be supplying them with adequate
VEGF-A for survival. Such a paracellular source of VEGF-
A is not likely to be easily inhibited by anti-VEGF-A drugs,
especiallybylargemoleculessuchasAﬂiberceptthatcannot
effectively enter the closely apposed smooth muscle cell- or
pericyte-endothelial cell interface.
The path forward
The data presented above indicate that anti-VEGF/VEGFR
therapy has serious limitations. Bevacizumab, accompa-
nied by chemotherapy, is able to prolong life marginally in
colon cancer and to delay progression modestly in several
other cancers. It seems unlikely that these results can be
much improved upon with other drugs targeting the VEGF-
A/VEGFR axis. However, a distinction needs to be made
between anti-VEGF-A/VEGFR and anti-vascular therapy.
The results targeting the former should not be interpreted
as a negation of the latter. Rather, the point to be made is
that there is a need for new targets beyond, or in addition
to, the VEGF-A/VEGFR axis. In particular, there is a need
to ﬁnd molecules in or on ‘‘late’’ blood vessels that can
serve as new targets. We expect our Ad-VEGF-A
164
approach to be useful in ﬁnding such targets. With it we
can develop large numbers of tumor ‘‘surrogate’’ blood
vessels of each type at local tissue sites in relatively pure
form and at different stages of their progression. This Ad-
VEGF-A
164 approach differs from another useful approach,
that of purifying blood vessels and their endothelial cells
directly from cancers using SAGE technology [31]. This
latter approach requires many hours during which changes
in gene expression may take place. Also, the endothelial
cells harvested come from blood vessels of all different
types, not just from those ‘‘late’’ vessels that may be most
fruitful for targeting.
Work in progress is making use of the Ad-VEGF-A
164
approach to identify genes that are highly expressed in
‘‘late’’ vessels but not in the normal vasculature. Tissues
harvested at varying times after Ad-VEGF-A
164 injection
are being harvested and subjected to gene chip and RT-PCR
analysis. The hope is to ﬁnd new potential targets that will
allow us to target ‘‘late’’ blood vessels. We appreciate the
difﬁculties that may accompany this approach. At least by
histology, ‘‘late’’ vessels such as FA, DV and VM differ less
from their normal counterparts than do the ‘‘early’’ vessels
such as MV and GMP that have no clearly established normal
counterparts. Nonetheless, we have already identiﬁed several
potential molecular targets that we will be investigating fur-
ther in the months ahead and hope that one or more of these
may be useful therapeutically.
Finally, it should be noted that our Ad-VEGF-A
164
model might also have a second use. It can provide a
valuable tool for screening anti-vascular drugs, as it allows
the assessment of drug effectiveness on each type of tumor
‘‘surrogate’’ blood vessel. We suggest that this model can
Clin Exp Metastasis (2012) 29:657–662 661
123serve as a rapid and relatively inexpensive means for
screening the effectiveness of new anti-vascular drugs as
they are developed.
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